phosphorylcholine has been researched along with Carcinoma, Epidermoid in 16 studies
Phosphorylcholine: Calcium and magnesium salts used therapeutically in hepatobiliary dysfunction.
phosphocholine : The phosphate of choline; and the parent compound of the phosphocholine family.
| Excerpt | Relevance | Reference |
|---|---|---|
| " The APL prototype edelfosine was previously found to be endocytosed by S49 mouse lymphoma cells via lipid rafts." | 3.74 | Lipid rafts and metabolic energy differentially determine uptake of anti-cancer alkylphospholipids in lymphoma versus carcinoma cells. ( Klarenbeek, JB; van Blitterswijk, WJ; van der Luit, AH; Verheij, M; Vink, SR, 2007) |
| "Perifosine is an oral alkylphospholipid that inhibits AKT phosphorylation and has shown preclinical antitumor activity in head and neck cancer cell lines and xenografts." | 2.72 | A phase II trial of perifosine, an oral alkylphospholipid, in recurrent or metastatic head and neck cancer. ( Ansari, R; Argiris, A; Cohen, E; Dancey, J; Esparaz, B; Karrison, T; Lu, Y; Mauer, A; Pins, M; Vokes, E; Wong, S, 2006) |
| " In addition, at the highest dosage group in rats, an increase in white blood cell counts (WBC) was observed." | 2.67 | Increases in leucocyte and platelet counts induced by the alkyl phospholipid hexadecylphosphocholine. ( Drogendijk, TE; Oosterom, R; Planting, AS; Pronk, LC; Stoter, G; Verweij, J, 1994) |
| "Perifosine was not metabolized and displayed slow elimination, with a terminal half-life of 137 (+/- 20) hours and an apparent volume of distribution of 11." | 1.33 | Tumor and normal tissue pharmacokinetics of perifosine, an oral anti-cancer alkylphospholipid. ( Schellens, JH; van Blitterswijk, WJ; Verheij, M; Vink, SR, 2005) |
| "In vivo, the response of human KB squamous cell carcinoma xenografts was measured after treatment with perifosine, irradiation, and the combination." | 1.33 | Radiosensitization of squamous cell carcinoma by the alkylphospholipid perifosine in cell culture and xenografts. ( Begg, AC; Lagerwerf, S; Mesman, E; Schellens, JH; van Blitterswijk, WJ; Verheij, M; Vink, SR, 2006) |
| "Miltefosine was highly active against the human KB tumour xenograft in nude mice, leading to growth inhibition as well as regression of large established tumours, which suggested that its mode of action was not mediated by the T cell system." | 1.28 | Investigation into the immunological effects of miltefosine, a new anticancer agent under development. ( Hilgard, P; Kampherm, E; Nolan, L; Pohl, J; Reissmann, T, 1991) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 6 (37.50) | 18.2507 |
| 2000's | 7 (43.75) | 29.6817 |
| 2010's | 3 (18.75) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ansari, SS | 1 |
| Sharma, AK | 1 |
| Soni, H | 1 |
| Ali, DM | 1 |
| Tews, B | 1 |
| König, R | 1 |
| Eibl, H | 1 |
| Berger, MR | 1 |
| Prieto, MD | 1 |
| Uribe-Restrepo, AF | 1 |
| Arcos, D | 1 |
| Vargas, DA | 1 |
| Fu, L | 1 |
| Lin, YD | 1 |
| Elrod, HA | 1 |
| Yue, P | 1 |
| Oh, Y | 1 |
| Li, B | 1 |
| Tao, H | 1 |
| Chen, GZ | 1 |
| Shin, DM | 1 |
| Khuri, FR | 1 |
| Sun, SY | 1 |
| Mahieu-Renard, L | 1 |
| Richard, MA | 1 |
| Dales, JP | 1 |
| Buscaylet, S | 1 |
| Lagrassa, S | 1 |
| Grob, JJ | 1 |
| Vink, SR | 3 |
| Schellens, JH | 2 |
| van Blitterswijk, WJ | 3 |
| Verheij, M | 3 |
| Lagerwerf, S | 1 |
| Mesman, E | 1 |
| Begg, AC | 1 |
| Argiris, A | 1 |
| Cohen, E | 1 |
| Karrison, T | 1 |
| Esparaz, B | 1 |
| Mauer, A | 1 |
| Ansari, R | 1 |
| Wong, S | 1 |
| Lu, Y | 1 |
| Pins, M | 1 |
| Dancey, J | 1 |
| Vokes, E | 1 |
| Preetha, A | 1 |
| Huilgol, N | 1 |
| Banerjee, R | 1 |
| van der Luit, AH | 1 |
| Klarenbeek, JB | 1 |
| Pronk, LC | 1 |
| Planting, AS | 2 |
| Oosterom, R | 1 |
| Drogendijk, TE | 1 |
| Stoter, G | 3 |
| Verweij, J | 3 |
| Avila, MA | 1 |
| Otero, G | 1 |
| Cansado, J | 1 |
| Dritschilo, A | 1 |
| Velasco, JA | 1 |
| Notario, V | 1 |
| Gandia, D | 1 |
| Armand, JP | 1 |
| Fu, D | 1 |
| Shi, Z | 1 |
| Wang, Y | 1 |
| Patel, V | 1 |
| Lahusen, T | 1 |
| Sy, T | 1 |
| Sausville, EA | 1 |
| Gutkind, JS | 1 |
| Senderowicz, AM | 1 |
| Planting, A | 1 |
| van der Burg, M | 1 |
| Hilgard, P | 1 |
| Kampherm, E | 1 |
| Nolan, L | 1 |
| Pohl, J | 1 |
| Reissmann, T | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase II Study Of Perifosine In Patients With Recurrent Or Metastatic Head And Neck Cancer[NCT00062387] | Phase 2 | 46 participants (Actual) | Interventional | 2003-05-31 | Terminated (stopped due to Administratively complete.) | ||
| Phase 3 Open-label Study of Efficacy and Safety of Miltefosine or Thermotherapy vs Glucantime for Cutaneous Leishmaniasis in Colombia.[NCT00471705] | Phase 3 | 437 participants (Actual) | Interventional | 2006-06-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"Complete Clinical response: Initial cure plus the absence of recurrences or mucosal lesions for 6 months after the end of treatment.~Note: nitial cure: Complete re-epithelialization of all ulcers and complete disappearance of the induration up to 3 months after the end of treatment." (NCT00471705)
Timeframe: Until 6 months posttreatment
| Intervention | participants (Number) |
|---|---|
| Miltefosine | 85 |
| Glucantime® | 103 |
| Thermotherapy | 86 |
At least 50% increase in lesion size at the end of treatment, absence of clinical response at 6 weeks, or any sign of lesion activity 3 months after the end of treatment (NCT00471705)
Timeframe: Until 3 months posttreatment
| Intervention | participants (Number) |
|---|---|
| Miltefosine | 34 |
| Glucantime® | 14 |
| Thermotherapy | 42 |
Reactivation of the lesion at the original site after cure or mucosal compromise during follow-up. (NCT00471705)
Timeframe: Until 6 months post-treatment
| Intervention | Participants (Number) |
|---|---|
| Miltefosine | 3 |
| Glucantime® | 4 |
| Thermotherapy | 6 |
4 trials available for phosphorylcholine and Carcinoma, Epidermoid
| Article | Year |
|---|---|
A phase II trial of perifosine, an oral alkylphospholipid, in recurrent or metastatic head and neck cancer.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Carc | 2006 |
Increases in leucocyte and platelet counts induced by the alkyl phospholipid hexadecylphosphocholine.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Carcinoma, | 1994 |
Phase II study of oral miltefosine in patients with squamous cell head and neck cancer.
Topics: Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Female; Head and Neck Neoplasms; Humans; Male | 1993 |
A dose-finding study of miltefosine (hexadecylphosphocholine) in patients with metastatic solid tumours.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Colore | 1992 |
12 other studies available for phosphorylcholine and Carcinoma, Epidermoid
| Article | Year |
|---|---|
Induction of ER and mitochondrial stress by the alkylphosphocholine erufosine in oral squamous cell carcinoma cells.
Topics: Annexin A5; Antineoplastic Agents; Apoptosis; Autophagy; Calcium; Carcinoma, Squamous Cell; Cell Lin | 2018 |
Case Report: Squamous Cell Carcinoma Referred for Mohs Surgery Found to be Cutaneous Leishmaniasis.
Topics: Antibodies, Protozoan; Antiprotozoal Agents; Carcinoma, Squamous Cell; Diagnosis, Differential; Fema | 2018 |
c-Jun NH2-terminal kinase-dependent upregulation of DR5 mediates cooperative induction of apoptosis by perifosine and TRAIL.
Topics: Animals; Anthracenes; Antineoplastic Agents; Apoptosis; Blotting, Western; Carcinoma, Squamous Cell; | 2010 |
[Treatment of cutaneous metastases of a squamous cell carcinoma of the leg with topical miltefosine].
Topics: Administration, Topical; Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Female; Humans; Leg; | 2005 |
Tumor and normal tissue pharmacokinetics of perifosine, an oral anti-cancer alkylphospholipid.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Carcinoma, Squamous Cell; Cell Line, Tumor; Ce | 2005 |
Radiosensitization of squamous cell carcinoma by the alkylphospholipid perifosine in cell culture and xenografts.
Topics: Animals; Apoptosis; Carcinoma, Squamous Cell; Combined Modality Therapy; Female; G2 Phase; Head and | 2006 |
Effect of fluidizing agents on paclitaxel penetration in cervical cancerous monolayer membranes.
Topics: 1,2-Dipalmitoylphosphatidylcholine; Antineoplastic Agents, Phytogenic; Carcinoma, Squamous Cell; Cel | 2007 |
Lipid rafts and metabolic energy differentially determine uptake of anti-cancer alkylphospholipids in lymphoma versus carcinoma cells.
Topics: Adenosine Triphosphate; Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Squamous Cell; Cell Li | 2007 |
Activation of phospholipase D participates in signal transduction pathways responsive to gamma-radiation.
Topics: Carcinoma, Squamous Cell; Choline; Enzyme Activation; Gamma Rays; Glycerophospholipids; Glycerylphos | 1993 |
Bcl-2 plays a key role instead of mdr1 in the resistance to hexadecylphosphocholine in human epidermoid tumor cell line KB.
Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Drug Design; Drug Resistance; Gene Expression; Gene | 1999 |
Perifosine, a novel alkylphospholipid, induces p21(WAF1) expression in squamous carcinoma cells through a p53-independent pathway, leading to loss in cyclin-dependent kinase activity and cell cycle arrest.
Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; CDC2 Protein Kinase; Cell Cycle; Cell Division; Cyc | 2002 |
Investigation into the immunological effects of miltefosine, a new anticancer agent under development.
Topics: Animals; Antibody Formation; Antineoplastic Agents; Carcinoma, Squamous Cell; Female; Humans; Immuni | 1991 |